KURA ONCOLOGY, INC. Available-for-sale Securities, Current
KURA ONCOLOGY, INC. (KURA) had Available-for-sale Securities, Current of $166.85 million as of 2018-09-30, per its 10-Q filed 2018-11-05.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesCurrent · last filed 2018-11-05
- 2018-09-30: Available-for-sale Securities, Current $166.85M.
- 2018-06-30: Available-for-sale Securities, Current $108.23M.
- 2018-03-31: Available-for-sale Securities, Current $111.68M.
- 2017-12-31: Available-for-sale Securities, Current $81.71M.
| Period end | Available-for-sale Securities, Current |
|---|---|
| 2018-09-30 | $166.85M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $108.23M 10-Q · filed 2018-08-06 |
| 2018-03-31 | $111.68M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $81.71M 10-Q · filed 2018-11-05 |
| 2017-09-30 | $77.47M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $41.09M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $48.51M 10-Q · filed 2017-05-15 |
| 2016-12-31 | $58.06M 10-K · filed 2018-03-12 |
| 2016-09-30 | $67.78M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $67.98M 10-Q · filed 2016-08-10 |
| 2016-03-31 | $62.14M 10-Q · filed 2016-05-11 |
| 2015-12-31 | $70.30M 10-K · filed 2017-03-14 |
| 2015-09-30 | $30.02M 10-Q · filed 2015-11-13 |
| 2015-06-30 | $26.14M 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |